{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High+Dose+Drug+A&page=5",
    "query": {
      "intervention": "High Dose Drug A",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 1664,
    "total_pages": 167,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High+Dose+Drug+A&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High+Dose+Drug+A&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-07T13:45:29.924Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05878119",
      "title": "Effects of MIB-626 With and Without A High-Intensity Multi-Dimensional Exercise Training Program",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Investigational Product - MIB 626",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Standardized, progressive, high intensity, multidimensional exercise",
          "type": "OTHER"
        },
        {
          "name": "Usual Physical Activity",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Metro International Biotech, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "19 Years to 40 Years"
      },
      "enrollment_count": 124,
      "start_date": "2023-10-25",
      "completion_date": "2025-08-04",
      "has_results": false,
      "last_update_posted_date": "2026-01-21",
      "last_synced_at": "2026-11-07T13:45:29.924Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05878119"
    },
    {
      "nct_id": "NCT07839936",
      "title": "A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atherosclerosis",
        "Cardiovascular Disease",
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "VERVE-102",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Verve Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 175,
      "start_date": "2026-10",
      "completion_date": "2030-03",
      "has_results": false,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-11-07T13:45:29.924Z",
      "location_count": 1,
      "location_summary": "DeSoto, Texas",
      "locations": [
        {
          "city": "DeSoto",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07839936"
    },
    {
      "nct_id": "NCT01433965",
      "title": "Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 16,
      "start_date": "2012-08-08",
      "completion_date": "2021-01-12",
      "has_results": false,
      "last_update_posted_date": "2022-03-10",
      "last_synced_at": "2026-11-07T13:45:29.924Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01433965"
    },
    {
      "nct_id": "NCT06379217",
      "title": "NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Neuroendocrine Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "[68Ga]Ga-PSMA-11",
          "type": "DRUG"
        },
        {
          "name": "[68Ga]GA-DOTA-TATE",
          "type": "DRUG"
        },
        {
          "name": "[68Ga]Ga-NeoB",
          "type": "DRUG"
        },
        {
          "name": "[177Lu]Lu-PSMA-617",
          "type": "DRUG"
        },
        {
          "name": "[177Lu]Lu-DOTA-TATE",
          "type": "DRUG"
        },
        {
          "name": "[177Lu]Lu-NeoB",
          "type": "DRUG"
        },
        {
          "name": "L-Lysine HCl-L-Arginine HCl, 2.5 %,",
          "type": "DRUG"
        },
        {
          "name": "Gonadotropin-releasing hormone (GnRH) analogues",
          "type": "DRUG"
        },
        {
          "name": "GnRH antagonists",
          "type": "DRUG"
        },
        {
          "name": "Antiemetics & antinauseants",
          "type": "DRUG"
        },
        {
          "name": "Metoclopramide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "MALE",
        "summary": "18 Years to 100 Years · Male only"
      },
      "enrollment_count": 31,
      "start_date": "2024-07-29",
      "completion_date": "2026-10-09",
      "has_results": false,
      "last_update_posted_date": "2026-10-15",
      "last_synced_at": "2026-11-07T13:45:29.924Z",
      "location_count": 2,
      "location_summary": "Omaha, Nebraska • New York, New York",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06379217"
    },
    {
      "nct_id": "NCT06799065",
      "title": "First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Breast Cancer Recurrent",
        "Ovarian Cancer",
        "High-grade Serous Ovarian Carcinoma",
        "Triple Negative Breast Cancer",
        "sqNSCLC",
        "Squamous Non-small-cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "ATX-295",
          "type": "DRUG"
        },
        {
          "name": "ATX-295 and bevacizumab (or biosimilar)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Accent Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 218,
      "start_date": "2025-03-21",
      "completion_date": "2027-08-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-11-07T13:45:29.924Z",
      "location_count": 11,
      "location_summary": "Aurora, Colorado • Sarasota, Florida • Detroit, Michigan + 8 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06799065"
    },
    {
      "nct_id": "NCT01704365",
      "title": "RSV-F Vaccine Dose Ranging Study in Young Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Respiratory Syncytial Virus (RSV)"
      ],
      "interventions": [
        {
          "name": "Low dose RSV-F Vaccine with Adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Low dose RSV-F Vaccine without Adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "High dose RSV-F Vaccine with Adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "High dose RSV-F Vaccine without Adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Low dose RSV-F Vaccine with Adjuvant [Bedside Mixing]",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novavax",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 35 Years · Female only"
      },
      "enrollment_count": 330,
      "start_date": "2012-10",
      "completion_date": "2013-05",
      "has_results": false,
      "last_update_posted_date": "2014-03-07",
      "last_synced_at": "2026-11-07T13:45:29.924Z",
      "location_count": 4,
      "location_summary": "Anaheim, California • Rockville, Maryland • Mt. Pleasant, South Carolina + 1 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Rockville",
          "state": "Maryland"
        },
        {
          "city": "Mt. Pleasant",
          "state": "South Carolina"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01704365"
    },
    {
      "nct_id": "NCT02270788",
      "title": "Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Crenolanib",
          "type": "DRUG"
        },
        {
          "name": "Sorafenib",
          "type": "DRUG"
        },
        {
          "name": "methotrexate, hydrocortisone and cytarabine with leucovorin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "1 Year to 39 Years"
      },
      "enrollment_count": 10,
      "start_date": "2015-04-02",
      "completion_date": "2016-10-17",
      "has_results": false,
      "last_update_posted_date": "2017-10-03",
      "last_synced_at": "2026-11-07T13:45:29.924Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02270788"
    },
    {
      "nct_id": "NCT05327023",
      "title": "Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hematologic Neoplasms"
      ],
      "interventions": [
        {
          "name": "donor lymphocyte infusion",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "12 Years to 120 Years"
      },
      "enrollment_count": 430,
      "start_date": "2022-05-23",
      "completion_date": "2029-07-02",
      "has_results": false,
      "last_update_posted_date": "2026-10-16",
      "last_synced_at": "2026-11-07T13:45:29.924Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05327023"
    },
    {
      "nct_id": "NCT03388619",
      "title": "Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer Of Prostate",
        "Prostate Neoplasms",
        "Prostate Cancer",
        "Neoplasms of Prostate",
        "Prostatic Cancer"
      ],
      "interventions": [
        {
          "name": "Prostate bed with integrated boost",
          "type": "RADIATION"
        },
        {
          "name": "Prostate bed irradiation only",
          "type": "RADIATION"
        },
        {
          "name": "Whole Body Bone Scan",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "18F-NaF PET Imaging",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "CT",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "mpMRI",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "ADT",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DIAGNOSTIC_TEST",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 30,
      "start_date": "2018-01-17",
      "completion_date": "2025-12-04",
      "has_results": true,
      "last_update_posted_date": "2026-08-28",
      "last_synced_at": "2026-11-07T13:45:29.924Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03388619"
    },
    {
      "nct_id": "NCT04109222",
      "title": "Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Fluzone Quadrivalent vaccine, no preservative (0.5-mL), 2019-2020 formulation",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluzone High-Dose vaccine, 2019-2020 formulation",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "83 Years",
        "sex": "ALL",
        "summary": "6 Months to 83 Years"
      },
      "enrollment_count": 90,
      "start_date": "2019-09-30",
      "completion_date": "2019-12-10",
      "has_results": true,
      "last_update_posted_date": "2025-09-12",
      "last_synced_at": "2026-11-07T13:45:29.924Z",
      "location_count": 2,
      "location_summary": "Bardstown, Kentucky • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Bardstown",
          "state": "Kentucky"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04109222"
    }
  ]
}